EBRO 2017

First page Table of contents Previous page 1043 Next page Last page

Esophageal cancer: Neo-adjuvant Chemoradiotherapy or Chemotherapy?

EBRO 2017EBRO 2017

CT CRT

3-year survival: 27.7% (arm A) vs. 47.4% (arm B); p=0.07

Stahl et al. J Clin Oncol 2009

Made with FlippingBook Learn more on our blog